Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bacillus Bacteria
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : SporeGen
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SPOR COV product consists of a proprietary formulation of Bacillus bacteria that is administered nasally as a spray. It is being developed for for COVID-19 and Influenza.
Brand Name : SPOR-COV
Molecule Type : Vaccine
Upfront Cash : Not Applicable
May 02, 2023
Lead Product(s) : Bacillus Bacteria
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : SporeGen
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NTCD-M3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Sebela Pharmaceuticals
Deal Size : $570.0 million
Deal Type : Collaboration
Agreement with Sebela Pharmaceuticals for NTCD-M3
Details : Under the terms of the deal, Sebela will lead the future clinical development and commercialisation activities of NTCD-M3 in North America. NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. di...
Brand Name : NTCD-M3
Molecule Type : Large molecule
Upfront Cash : $1.0 million
February 24, 2023
Lead Product(s) : NTCD-M3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Sebela Pharmaceuticals
Deal Size : $570.0 million
Deal Type : Collaboration
Lead Product(s) : NTCD-M3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : finnCap Limited
Deal Size : $9.6 million
Deal Type : Financing
Destiny Pharma Announces Fundraising Upto £8 Million
Details : The net proceeds of the Fundraising will allow the Company to complete final Phase 3 clinical trial preparation for NTCD-M3, Destiny pharma’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence.
Brand Name : NTCD-M3
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 24, 2023
Lead Product(s) : NTCD-M3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : finnCap Limited
Deal Size : $9.6 million
Deal Type : Financing
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel
Details : XF-73 reduced the mean nasal burden of S. aureus in patients undergoing open heart surgery by 2.5 log (CFU/ml) in the 24 hours immediately before surgery in the micro-ITT (Intend to Treat) population, a statistically highly significant result.
Brand Name : XF-73
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 29, 2021
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Destiny Pharma Completes Phase 2b Clinical Trial of XF-73 Patient Recruitment
Details : XF-73 is a first-in-class drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of postsurgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus.
Brand Name : XF-73
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2021
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NTCD-M3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Update On the Recently Acquired NTCD-M3 Programme
Details : Destiny Pharma reported that it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the prevention of C. difficile infection (CDI) recurrence.
Brand Name : NTCD-M3
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 22, 2020
Lead Product(s) : NTCD-M3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SPOR-COV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : SporeGen
Deal Size : $1.0 million
Deal Type : Collaboration
Details : Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.
Brand Name : SPOR-COV
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 08, 2020
Lead Product(s) : SPOR-COV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : SporeGen
Deal Size : $1.0 million
Deal Type : Collaboration
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Destiny Pharma’s Novel Antibiotic Asset XF-73 Clears Safety Review
Details : Positive interim safety review has been completed by an Independent Data Monitoring Committee (IDMC) of the Company’s ongoing Phase 2b study of its lead asset XF-73 in the prevention of post-surgical bacterial infections.
Brand Name : XF-73
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 11, 2020
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Destiny Pharma Provides Update on its Phase 2b Clinical Study of XF-73
Details : Destiny Pharma agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value. The study is evaluating XF-73 for the prevention of post-surgical hospital infections caused by Staphylococcus aureus bacteria, su...
Brand Name : XF-73
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 27, 2020
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data published to date support the unique target profile of XF-73 and its potential to address the threat of AMR.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 04, 2020
Lead Product(s) : Exeporfinium chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?